Development of targeted adjuvants for HIV-1 vaccines

about

HIV vaccine research in Canada.

P2860

Q42357492-39DBA22B-1394-4A35-B716-84D6270A45B3

P2860

Development of targeted adjuvants for HIV-1 vaccines

Item

http://www.wikidata.org/entity/Q41277922

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Development of targeted adjuvants for HIV-1 vaccines

@en

type

Item

label

Development of targeted adjuvants for HIV-1 vaccines

@en

prefLabel

Development of targeted adjuvants for HIV-1 vaccines

@en

P1476

Development of targeted adjuvants for HIV-1 vaccines

@en

P2093

Jun Liu

http://www.w3.org/2001/XMLSchema#string

Mario Ostrowski

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL

BAFF, APRIL and their receptors: structure, function and signaling

Impact of the BAFF/BR3 axis on B cell survival, germinal center maintenance and antibody production

APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells

BCMA is essential for the survival of long-lived bone marrow plasma cells

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination.

CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge

Antibody persistence and T-cell balance: two key factors confronting HIV vaccine development.

P2888

s12981-017-0165-8

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1186/S12981-017-0165-8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P5008

ScienceSource

P577

2017-09-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1091451820

http://www.w3.org/2001/XMLSchema#string

P698

28893282

http://www.w3.org/2001/XMLSchema#string

P921

human immunodeficiency virus infectious disease

Retroviridae infectious disease

P932

5594534

http://www.w3.org/2001/XMLSchema#string

Development of targeted adjuvants for HIV-1 vaccines

about

P2860

P2860

Development of targeted adjuvants for HIV-1 vaccines

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P2888

P304

P31

P356

P433

P478

P5008

P577

P6179

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P2888

P304

P31

P356

P433

P478

P5008

P577

P6179

P698

P921

P932